Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents

Duchmann, Matthieu; P. Braun, Theodore; Micol, J.B.; Platzbecker, Uwe; Park, Sophie; Pilorge, Sylvain; Beyne‐Rauzy, Odile; Vey, Norbert; Sébert, Marie; Gruson, Bérengère; Dumas, P-Y; Guièze, Romain; Chretien, M-L; Laribi, K; Chait, Y; Legros, Laurence; Sahnes, Laurence; Hirsch, Pierre; Salanoubat, Célia; Solary, Éric; Fenaux, P.; Itzykson, Raphaël

doi:10.1038/bcj.2017.41

Public

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents

Published in Blood Cancer Journal • May 12, 2017

Authors:

Matthieu Duchmann

Theodore P. Braun

J.B. Micol

Abstract

The hypomethylating agents (HMA) azacitidine (AZA) 1 , 2 and decitabine (DAC) 3 , 4 are active in Chronic Myelomonocytic Leukemia (CMML) with overall response rates (ORR) of 40–70%, translating into median overall survivals (OS) of 12–22 months. Response to HMA in these CMML cohorts was mostly evalu...

Subject

Chronic myelomonocytic leukemia

Medicine

Azacitidine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!